DURHAM – Life sciences giant Iqvia is teaming with international pharmacerutical firm AstraZeneca in an attempt to accelerate development of a COVID-19 vaccine.
The companies announced the effort Tuesday morning. Financial terms were not disclosed.
Several Triangle area companies are involved in other COVID-19 vaccine and treatment efforts.
The AstraZeneca-Iqvia partnership will be included in the “Operation Warp Speed” COVID-19 vaccine effort launched by the Trump Administration.
“The specific IQVIA and AstraZeneca collaboration will drive faster delivery of clinical studies in the U.S. aimed at demonstrating efficacy of AstraZeneca’s potential COVID-19 vaccine, AZD1222,” Iqvia said in the announcement.
“This initiative includes an expansive subject study, which is expected to begin enrolling participants this summer and will leverage IQVIA’s Virtual Trial solutions including Study Hub.”
